MUTA抗体;MUTA Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of MUTA expression in HeLa cell lysate.    

  
  

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

MUTA antibodies (Mutation-Targeting Antibodies) are a class of therapeutic or diagnostic agents designed to specifically recognize and bind to mutated proteins associated with diseases, particularly cancer. Their development stems from advances in genomic sequencing, which identified somatic mutations driving tumorigenesis, such as in EGFR, KRAS, or TP53. Unlike traditional antibodies targeting wild-type antigens, MUTA antibodies focus on neoantigens—unique protein fragments arising from genetic alterations in cancer cells. This specificity minimizes off-target effects, enhancing treatment precision.

The concept gained traction with the rise of personalized oncology, where therapies are tailored to a patient’s unique mutational profile. Early successes include antibodies targeting EGFR mutations (e.g., osimertinib for EGFR T790M-positive lung cancer) and immune checkpoint inhibitors leveraging tumor mutation burden as a biomarker. MUTA antibodies often employ hybridoma technology, phage display, or recombinant engineering for high-affinity binding. Challenges include tumor heterogeneity, antigen loss, and immune evasion. Current research explores bispecific formats, combination therapies, and AI-driven epitope prediction to improve efficacy. Their application extends beyond oncology to autoimmune and infectious diseases, where mutation-specific targeting could address drug resistance or pathogen variability.